Study	Efficacy	Participants with at least one adverse event	Serious adverse events	Withdrawals
Goldenberg 1986 USA	No significant difference between naproxen and placebo on any measure	Naproxen 2/19 Placebo 2/19 Each had 1 dyspepsia, and 1 diarrhoea	None reported	1 naproxen (not returned) 1 placebo (epigastric distress)
Kravitz 1994 USA	No significant difference between naproxen and placebo on any measure	AE data not reported in straightforward way	1 ibuprofen sedation, memory problems, impaired mentation	1 ibuprofen due to pre‐existing skin problem 14 did not complete all five weeks due to lack of efficacy, but data not given by treatment
Mahagna 2016 NCT00755521 Israel	50% pain intensity reduction etoricoxib 4/32 placebo 6/32 30% pain intensity reduction etoricoxib 9/32 placebo 9/32 No significant difference FIQ No significant difference in SF‐36 No significant difference in HARS or HADS scales	Total AE etoricoxib 10/32 placebo 13/32	None	All cause etoricoxib 3/32 placebo 2/32 AE withdrawal etoricoxib 2/32 placebo 0/32 LoE withdrawal etoricoxib 0/32 placebo 0/32
Quijada‐Carrera 1996 Spain	Clinically significant improvement tenoxicam 4/41 placebo 7/41 25% reduction in pain tenoxicam 6/41 placebo 9/41 No difference in number of tender points, sleep quality, or morning stiffness	At least 1 AE tenoxicam 18/41 placebo 7/41	None reported	All cause tenoxicam 17/41 placebo 15/41 AE withdrawal tenoxicam 3/41 placebo 1/41 LoE withdrawal tenoxicam 4/41 placebo 3/41
Russell 1991 USA	No significant difference reported between ibuprofen and placebo for any outcome	No data	None reported	AE withdrawals ibuprofen 0 placebo 4
Yunus 1989 USA	Mean pain score 2.4 in both groups at 3 weeks No significant difference for sleep, morning fatigue, stiffness, or other symptoms Moderate or complete pain relief at 3 weeks ibuprofen 6/22 placebo 7/24	At least one AE ibuprofen 5/22 placebo 4/24	None reported	All cause withdrawal by week 3 ibuprofen 2/22 placebo 2/24 AE withdrawal ibuprofen 1/22 placebo 0/24